Pharmacotherapy for Vascular Cognitive Impairment

@article{Farooq2017PharmacotherapyFV,
  title={Pharmacotherapy for Vascular Cognitive Impairment},
  author={Muhammad Umar Farooq and Jiangyong Min and Christopher Goshgarian and Philip B. Gorelick},
  journal={CNS Drugs},
  year={2017},
  volume={31},
  pages={759-776}
}
Vascular cognitive impairment (VCI) is the second most common type of dementia after Alzheimer’s disease (AD). Stroke and cardiovascular risk factors have been linked to both AD and VCI and potentially can affect cognitive function in mid and later life. Various pharmacological agents, including donepezil, galantamine, and memantine, approved for the treatment of AD have shown modest cognitive benefits in patients with vascular dementia (VaD). However, their functional and global benefits have… Expand
Vascular cognitive impairment: pathophysiological mechanisms, insights into structural basis, and perspectives in specific treatments
TLDR
This review focuses on factors contributing to cerebrovascular disease, neurovascular unit alterations, and novel approaches to cognitive improvement in patients with cognitive decline and the prospective role of a novel complex drug consisting of released–active antibodies to S100 and to endothelial NO synthase in VCI treatment. Expand
Vascular Cognitive Impairment: Information from Animal Models on the Pathogenic Mechanisms of Cognitive Deficits
TLDR
This review summarizes the information from animal models on the molecular changes that occur in the brain during a cerebral vascular insult and ultimately lead to cognitive deficits in VCI. Expand
Stem cells and vascular dementia: from basic science to the clinic
TLDR
Evidence suggested that stem cell transplantation could improve the symptoms of cerebral infarction and AD and it may serve as a potential therapy for VD, was summarized both in vitro and in vivo. Expand
Progression in Vascular Cognitive Impairment: Pathogenesis, Neuroimaging Evaluation, and Treatment
TLDR
The pathogenesis, neuroimaging evaluation, and treatment of VCI are discussed, which focuses on neurological protection, cerebral blood flow reconstruction, and neurological rehabilitation, such as pharmacological treatment, revascularization, and cognitive training. Expand
Definition and Concept of Vascular Cognitive Impairment
TLDR
The epidemiology and the evolution of diagnostic criteria for dementia with special emphasis on vascular cognitive impairment are reviewed and the contribution of vascular risk factors to neurodegeneration and novel strategies to prevent or delay cognitive decline are discussed. Expand
Emerging Concepts in Vascular Dementia: A Review.
TLDR
An updated overview of the epidemiology, pathophysiological mechanisms, neuroimaging patterns as well as current diagnostic and therapeutic approaches on vascular dementia is provided. Expand
Cognitive Impairment in Patients with Stroke.
Despite substantial advances in stroke care, vascular cognitive impairment remains a prominent source of disability. Unlike sensorimotor impairments, cognition often continues to decline afterExpand
Citicoline in the Treatment of Cognitive Impairment
  • J. Secades
  • Biology
  • Journal of Neurology and Experimental Neuroscience
  • 2019
TLDR
An updated review of the possible use of citicoline in the treatment of cognitive impairment and the etiology of this kind of impairment is given. Expand
Roles of glutamate receptors in a novel in vitro model of early, comorbid cerebrovascular, and Alzheimer’s diseases
TLDR
A novel in vitro model of comorbid CVD/AD in organotypic hippocampal cultures is developed, by combining oxygen‐glucose deprivation and exposure to amyloid‐Aβ oligomers, which synergized to reduce levels of synaptophysin and PSD‐95 without cell death and helps understand variable responses to glutamate receptor antagonists in patients diagnosed with AD. Expand
Current status and future prospects of pathophysiology-based neuroprotective drugs for the treatment of vascular dementia.
TLDR
This review highlights the pathophysiology, current pharmacology-based primary and secondary prevention strategies and emerging treatment options for vascular dementia. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 119 REFERENCES
Rivastigmine for vascular cognitive impairment.
TLDR
The efficacy of rivastigmine compared with placebo in the treatment of people with vascular cognitive impairment (VCI), vascular dementia or mixed dementia was assessed and no significant difference was found on any outcome measure relevant to cognition, neuropsychiatric symptoms, function or global rating. Expand
Galantamine for vascular cognitive impairment.
TLDR
The data available at the time of review suggest some advantage over placebo in the areas of cognition and executive functioning in one trial but this was not seen in a second trial which included smaller numbers of relevant patients, and more studies are needed before firm conclusions can be drawn. Expand
The rationale behind cholinergic drug treatment for dementia related to cerebrovascular disease
TLDR
Some interesting findings are covered which indicate the potential of galantamine to modulate other neurotransmitter systems (e.g. serotonergic, dopaminergic), which may be of specific relevance in the behavioral symptoms of dementia related to CVD. Expand
Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial
TLDR
Galantamine showed a therapeutic effect on all key areas of cognitive and non-cognitive abilities in this group of dementia patients and was well tolerated. Expand
Piracetam for dementia or cognitive impairment.
TLDR
The evidence available from the published literature does not support the use of piracetam in the treatment of people with dementia or cognitive impairment, and no benefit was shown by any of the more specific measures. Expand
Long-Term Treatment with Citicoline May Improve Poststroke Vascular Cognitive Impairment
TLDR
Citicoline treatment for 12 months in patients with first-ever ischemic stroke is safe and probably effective in improving poststroke cognitive decline and appears to be a promising agent to improve recovery after stroke. Expand
Donepezil in Vascular Dementia: Combined Analysis of Two Large-Scale Clinical Trials
TLDR
This combined analysis of the largest trial on VaD to date showed that donepezil-treated patients had significant benefits in cognition, global function and ability to perform IADL. Expand
Clinical Trials in Dementia with Propentofylline a
TLDR
Propentofylline showed statistically significant, clinically relevant improvements over placebo in efficacy assessments, both in Patients with Alzheimer's disease and in patients with vascular dementia, and was also well tolerated. Expand
Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL
TLDR
Donepezil had no effect on the primary endpoint, the V-ADAS-cog score in CADASIL patients with cognitive impairment, and improvements were noted on several measures of executive function, but the clinical relevance of these findings is not clear. Expand
Rivastigmine in subcortical vascular dementia An open 22-month study
TLDR
Improvements in domains particularly relevant to this condition were observed in patients treated with rivastigmine, which may reflect the drug's dual inhibitory effects on the cholinergic system, and its particular activity in frontal areas of the brain. Expand
...
1
2
3
4
5
...